Enzyme Replacement Therapy in CLN2-Associated Retinopathy

Area of Science:

• Neuroscience
• Genetics
• Ophthalmology

Background:

• Neuronal ceroid lipofuscinoses (Batten disease) are rare genetic neurodegenerative disorders.
• CLN2 disease, caused by TPP1 gene mutations, leads to progressive vision loss and neurological decline.
• Current intracerebroventricular enzyme replacement therapy (ERT) for CLN2 disease slows psychomotor decline but not vision loss.

Purpose of the Study:

• To review current knowledge on ERT for CLN2 retinopathy.
• To evaluate the safety and efficacy of intravitreal recombinant human TPP1 (rhTPP1) in preserving visual function.
• To discuss the potential of intravitreal ERT as a bridging therapy.

Main Methods:

• Review of existing literature on ERT for CLN2 disease.
• Analysis of a compassionate-use study of intravitreal rhTPP1.
• Discussion of ongoing and planned clinical trials.

Main Results:

• Intravitreal rhTPP1 demonstrated safety and efficacy in reducing macular volume loss in a canine model and human patients.
• The treatment markedly delays retinal degeneration, preserving visual function.
• ERT for CLN2 retinopathy appears safe and improves patients' quality of life.

Conclusions:

• Intravitreal rhTPP1 is a safe and effective treatment for CLN2 retinopathy.
• This therapy can preserve visual function and enhance quality of life for affected individuals.
• Intravitreal ERT may serve as a crucial bridging therapy until more definitive treatments like gene therapy are available.